Radioterapie u folikulárního lymfomu.
Stará historie v nové perspektivě?
Authors:
A. Janíková 1; J. Gombošová 2; I. Čoupková 2; J. Michalka 1; I. Vášová 1; J. Mayer 1
Authors‘ workplace:
Interní hematoonkologická klinika Lékařské fakulty Masarykovy Univerzity, Fakultní nemocnice Brno
1; Klinika radiační onkologie Lékařské fakulty Masarykovy univerzity, Masarykův onkologický ústav Brno
2
Published in:
Transfuze Hematol. dnes,16, 2010, No. 4, p. 210-217.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
Follicular lymphoma (FL) is the most common type of low grade malignant B-cell non-Hodgkin’s lymphoma. Despite of low proliferation, FL belongs to the extremely radiosensitive tumors. The high radiosensitivity is evident from rapid onset of efficacy early during first doses of irradiation and from good global results of low dose total body irradiation (1-2 Gy). Involved field radiotherapy (IF RT) is a standard therapeutic procedure especially in the localized stages of disease. In the case of extended FL, now, a therapy is based on combination of rituximab with chemotherapy, and radiotherapy is used as an auxiliary method in a small proportion of patients only. The doses between 25 and 40 Gy are usually used. Recently, there is increasing amount of evidence concerning very low radiation doses (2x2 Gy) in recurrent follicular lymphoma with significant efficacy. Low dose radiotherapy probably leads to the induction of apoptosis via p53 pathway. This hypothesis is in accordance with a theory of FL being a disease resistant to the apoptosis. IF radiotherapy 2x2 Gy offers an extremely attractive treatment possibility with minimal toxicity that is applicable also in heavily pretreated patients and that, moreover, could be administered with success repeatedly.
Key words:
follicular lymphoma, low dose radiotherapy, rituximab, microenvironment
Sources
1. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkinęs lymphomas: distributions of the major subtypes digger by geographic locations. Non-Hodgkinęs Lymphoma Classification Project. Ann Oncol 1998; 9: 717-720.
2. ÚZIS ČR, NOR ČR 2009 http://www.linkos.cz/odbornici/onkologie/nor.php
3. Dubray B, Breton Ch, Delic J, et al. In vitro radiation apoptosis and early response to low-dose radiotherapy in non-Hodgkinęs lymphomas. Radiother Oncol 1998; 46: 185-191.
4. Delic J, Magdelenat H, Barbaroux C, et al. In vivo induction of apoptosis in human lymphocytes by therapeutic fractionated total body irradiation. Br J Radiol 1995: 68: 997-1003
5. Joiner MC, Lambin P, Malaise EP, et al. Hypersensitivity to very-low single radiation doses. Mutat Res 1996; 358: 171-183.
6. Macmanus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996; 14: 1282-90.
7. Meerwaldt JH, Carde P, Burgers JM, et al. Low-dose total body irradiation versus combination chemotherapy for lymphomas with follicular growth pattern. Int J Radit Oncol Biol Phys 1991; 21: 1167-1172.
8. Lybeert ML, Meerwaldt JH, Deneve W. Long-term results of low dose body irradiation for advanced non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 1987; 13: 1167-1172.
9. Jacobs P, Kong HS. A randomized prospective comparison of chemotherapy to total body irradiation as initial treatment for the indolent lymphoproliferative diseases. Blood 1987; 69: 1642-1646.
10. Emmanouilides CE, Witzig TE, Gordon LI, et al. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkinęs lymphoma. Leukemia Lymph 2006; 47: 629-636.
11. Goff L, Summers K, Iqbal S, et al. Quantitative PCR analysis PCR analysis for Bcl-2/IgH in a phase III study of Ytrium Tiuxetan as consolidation of first remission in patiens with follicular lymphoma. J Clin Oncol 2009; 27: 6094-6100.
12. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of ytrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkinęs lymphoma. J Clin Oncol 2003; 20: 2453-2463.
13. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkinęs lymphoma. J Clin Oncol 2002; 20: 3262-3269.
14. Galteland E, Sivertsen EA, Svendsrud DH, et al. Translocation t(14;18) and gain of chromosome 18/Bcl2; effects on BCL-2 expression and apoptosis in B-cell non-Hodgkinęs lymphomas. Leukemia 2005; 19: 2313-2323.
15. ICRU: Prescribing, recording, and reporting photon beam therapy. In ICRU report. Volume 50. Bethesda: International Commission on Radiation Units and Measurements; 1993.
16. Hynková L, Šlampa P, et al. Radiační onkologie – učební texty, MOÚ, Brno, 2009, 242 s.
17. Perez CA, Brady LW, et al. Principles and practice of radiation oncology. 5th ed. Philadelphia: Lippincot Wiliams and Wilkins, 2008, 2106 s.
18. Gosselin M, Podgorsak EB, Evans MD, et al. A technique using parallel-opposed high energy electron beams for reirradiation of tumors near the spinal cord. Int J Radiat Oncol Biol Phys 1993; 27: 1207-1214.
19. Šlampa P, Petera J, et al. Radiační onkologie. Galén-Karolinum, Praha, 2007, 457 s.
20. Ha CS, Tucker SL, Blanco AI, et al. Hematologic recovery after central lymphatic irradiation for patiens with stage I-III follicular lymphoma. Cancer 2001; 92: 1074-1079.
21. Jacobs JP, Murray KJ, Schultz CJ, et al. Central lymphatic irradiation for stage III nodular malignant lymphoma: Long-term results. J Clin Oncol 1993; 11: 233-238.
22. Murtha AD, Knox SJ, Hoppe RT, et al. Long-term follow-up of patients with stage III follicular lymphoma treated with primary radiotherapy at Stanford University. Int J Rad Oncol Biol Phys 2001; 49: 3-15.
23. Adkins DR, DiPersio F. Total body irradiation before an allogeneic stem cell transplantation: is there a magic dose? Curr Opin Hematol 2008; 15: 555-560.
24. Bieri S, Held C, Chapuis B, et al. Total body irradiation before allogeneic bone marrow transplantation: is more dose better? Int J Radiat Oncol Biol Phys 2001; 49: 1071-1077.
25. Demirer T, Buckner CD, Appelbaum Fr, et al. Busulfan, cyclophosphamide and fractioned total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. Bone Marrow Transplant 1996; 17: 341-346.
26. Geller RB, Devine SM, OęToole K, et al. Allogeneic bone marrow transplantation with matched unrelated donors for patients with hematologic malignancies using a preparative regimen of high-dose cyclophosphamide ad fractionated total body irradiation. Bone Marrow Transplant 1997; 3: 219-225.
27. Guadagnolo BA, Li S, Neuberg D, et al. Long-term outcome and mortality trends in early stage, grade 1-2 follicular lymphoma treated with radiation therapy. Int Radiat Oncol Biol Phys 2006; 64: 928-934.
28. Kamath SS, Marcus RB, Lunch JW, et al. The impact of radiotherapy dose and other treatment-related and clinical factors on in-field control in stage I and II non-hodgkinęs lymphoma. Int J Rad Oncol Biol Phys 1999; 44: 563-8.
29. Kelsey SM, Newland AC, Hudson GV, et al. A British National Lymphoma Investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkinęs lymphoma. J Clin Oncol 1994; 11: 19-25.
30. Lawrence TS, Urba WJ, Steinberg SM, et al. Retrospective analysis of stage I and II indolent lymphomas at the National Cancer Institute. Int J Rad Oncol Biol Phys 1988; 14: 417-24
31. Neumann H, Blanck H, Koch R, et al. Follicle center lymphoma: treatment results for stage I and II. Strahlenther Onkol 2003; 179: 840-846.
32. Pendlebury S, el Alwadi M, Ashley S, et al. Radiotherapy results in early stage low grade nodal non-Hodgkinęs lymphoma. Radiother Oncol 1995; 167-71.
33. Sack H, Hoederath A, Stuschke M, et al. Radiotherapy of follicle center lymphoma. Results of a German multicenter and prospective study. Members of the Study Group „NHL – early stages“. Strahlenther Onkol 1998; 174: 178-185.
34. Soubeyran P, Eghbali H, Bonichon F, et al. Localized follicular lymphomas: prognosis and surfoval of stages I and II in a retrospective series of 103 patients. Radiother Oncol 1988; 13: 91-8.
35. Taylor RE, Allan SG, McIntyre MA, et al. Low grade stage I and II non-Hodgkinęs lymphoma: results of treatment and relapse pattern following therapy. Clin Radiol 1988; 39: 287-290.
36. Vaughan Hudson B, vaughan Hudson G, MacLennan KA, et al. Clinical stage1 non-Hodgkinęs lymphoma: long-term follow-up study of patiens treated at Stanford University. J Clin Oncol 1996; 14: 1282-1290.
37. Wilder RB, Jones D, Tucker SL, et al. Long-term results with radiotherapy for Stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys 2001; 51: 1219-1227.
38. Haas RLM. Low dose radiotherapy in indolent lymphomas, enough is enough. Hematol Oncol 2009; 27: 71-81.
39. Tsang RW, Gospodarowicz MK. Low-grade Non-Hodgkinęs lymphomas. Semin Radiat Oncol 2007; 17: 198-205.
40. Petersen PM, Gospodarowicz M, Tsang R, et al. Long-term outcome in stage I and II follicular lymphoma following treatment with involved field radiation therapy alone. J Clin Oncol 2004; 22: 563.
41. Frank C, Zierhut D, Schultz-Ertner D, et al. Centroblastic-centrocytic non-Hodgkinęs lymphoma stage I-III: patterns of failure following radiotherapy. Strahlenther Onkol 2001; 177: 597-603.
42. Paryani SB, Hoppe RT, Cox RS, et al. Analysis of non-Hodgkinęs lymphomas with nodular and favorable histology, stages I and II. Cancer 1983; 52: 2300-2307.
43. Johnson RE, Canellos GP, Young RC, et al. Chemotherapy (cyclophosphamide, vincristine, and prednisone) versus radiotherapy (total body irradiation) for stage III-IV poorly differentiated lymphocytic lymphoma. Cancer Treat Rep 1978; 62: 321-325.
44. Travis LB, Weeks J, Curtis RE et al. Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkinęs lymphoma. J Clin Oncol 1996; 14: 565-571.
45. Gustavsson A, Osterman B, Cavallin-Stahl E. A systematic overview of radiation therapy effects in Non-Hodgkinęs lymphoma. Acta Oncol 2003; 42: 605-19.
46. Hoppe RT, Kushlan P, Kaplan HS, et al. The treatment of advanced stage of favorable histology non-Hodgkinęs lymphoma: A preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiation. Blood 1981; 58: 592-598.
47. Seymour JF, Pro B, Fuller LM, et al. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkinęs lymphoma. J Clin Oncol 2003; 21: 2115-2122.
48. Spry NA, Lamb DS, Vaughan Hudson G, et al. Localized grade I non-Hodgkinęs lymphoma: results of treatment with radiotherapy alone in 88 patients. Clin Oncol 1989; 1: 33-38.
49. Sutcliffe SB, Gospodarowicz MK, Bush RS, et al. Role of radiation therapy in localized non-Hodgkinęs lymphoma. Radiother Oncol 1985; 4: 211-223.
50. Janíková A, Bolcak K, Pavlik T, Mayer J, Kral Z. Value of [18F] Flurodeoxyglucose positron emission tomography in the management of follicular lymphoma: The end of dilemma? Clin Lymph Myeloma 2008; 8 (5): 287-293.
51. Lybeert ML, Meerwaldt JH, Deneve W. Long-term results of low dose total body irradiation for advanced non-Hodgkinęs lymphoma. Int J Radiat Oncol Biol Phys 1987; 13: 1167-1172.
52. Meerwaldt JH, Carde P, Burgers JM, et al. Low-dose total body irradiation versus combination chemotherapy for lymphomas with follicular growth pattern. Int J Radiat Oncol Biol Phys 1991; 21: 1167-1172.
53. De Los Santos JF, Mendenhall NP, Lynch JWJ. Is comprehensive lymphatic irradiation for low-grade non-Hodgkinęs lymphoma curative therapy? Long-term experience at a single institution. Int J Radiat Oncol Biol Phys 1997; 38: 3-8.
54. Ha CS, Cabanillas F, Lee MS, et al. Serial determination of the bcl-2 gene in the bone marrow and peripheral blood after central lymphatic irradiation for stages I-III follicular lymphoma: a preliminary report. Clin Cancer Res 1997; 3: 215-219.
55. Ganem G, Lambin P, Socie G, et al. Potential role for low-dose limited-field radiation therapy (2 x 2 Grays) in advanced low-grade NonHodgkinęs lymphomas. Hematol Oncol 1994; 12: 1-8.
56. Girinski T, Guillot-Vals D, Koscielny S, et al. A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment. Int J Rad Oncol Biol Phys 2001; 51: 148-155.
57. Haas RLM, Poortmans P, de Jong D, et al. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol 2003; 21: 2474-2480.
58. Johannsson J, Specht L, Mejer J, et al. Phase II study of palliative low-dose local radiotherapy in disseminated indolent non-Hodgkinęs lymphoma and chronic lymphocytic leukemia. Int J Rad Oncol Biol Phys 2002; 54: 1466-1470
59. Murthy V, Thomas K, Foo K, et al. Efficacy of palliative low-dose involved field radiation therapy in advanced lymphoma: a phase II study. Clin Lymph Myeloma 2008; 8: 241-245.
60. Luthy SK, Ng AK, Silver B, et al. Response to low-dose involved field radiotherpay in patients with non-Hodgkinęs lymphoma. Ann Oncol 2008; 19: 2043-2047.
61. Cleary ML, Galili N, Sklar J. Detection of a second t(14;18) breakpoint cluster region in human follicular lymphomas. J Exp Med 1986; 164: 315-320.
62. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 1986; 83: 5214-5218.
63. Dubray B, Breton C, Delic J, et al. In vitro radiation-induced apoptosis and tumor response to radiotherapy: a prospective study in patiens with non-Hodgkin lymphomas treated by low-dose irradiation. Int J Radiat Biol 1997; 72: 759-760.
64. Haas RLM, de Jong D, Valdes Olmos RA, et al. In vivo imaging of radiation-induced apoptosis in follicular lymphoma patiens. Int J Rad Oncol Biol Phys 2004; 59: 782-787.
65. Knoops L, Haas R, de Kemp S et al. In vivo p53 response and immune reaction underlie higly effective low-dose radiotherapy in follicular lymphoma. Blood 2007; 110: 1116-1122.
66. Kennedy AD, Solga MD, Schuman TA, et al. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood 2003; 101: 1071-1079.
67. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1988; 91: 1644-1652.
68. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.
69. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101-106.
70. Fortspointer R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 3064-3071.
71. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphoma as compared to CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group (GLSG). Blood 2005; 106: 3725-3732.
72. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417-1423.
73. DiGaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001; 114: 800-809.
74. Skvortsova I, Popper BA, Skvortsov S, et al. Pretreatment with rituximab enhances radiosensitivity of non-Hodgkinęs lymphoma cells. J Radiat Res 2005; 46: 241-248.
75. Skvortsova I, Skvortsov S, Popper BA, et al. Rituximab enhances radiation-triggered apoptosis in non-Hodgkinęs lymphoma cells via caspase-dependent and independent mechanisms. J Radiat Res 2006; 47: 183-196.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
![Issue 4](https://www.prolekare.cz/media/cache/resolve/journal_issue/media/image_pdf/6326d7471aee6460fae9bde02f962479.jpeg)
2010 Issue 4
Most read in this issue
- Contemporary classification diagnostic and prognosis of primary monoclonal gammopathies (paraproteinemias)
- Blood donation and iron stores – comparison of double erythrocytapheresis and whole blood donation
-
Radioterapie u folikulárního lymfomu.
Stará historie v nové perspektivě? - Treatment results of chronic myeloid leukemia patients in HOK Olomouc during 2000–2009: the prognostic significance of Sokalęs score and ELN criterions